Skip to content
CNBC Investing Club: Cramer’s Morning Take on Goldman Sachs 10/14/26 artwork

CNBC Investing Club: Cramer’s Morning Take on Goldman Sachs 10/14/26

Squawk on the Street

October 14, 2026

Cramer says this financial firm is the one investors want to buy.

Speakers Jim Cramer

TopicsNewsBusinessInvesting

SPEAKER_1 (0:00)

With the Discover Cashback card, it's payback time when you earn cash back on everyday purchases. Activate and earn 5 percent cash back at different categories each quarter on up to $1,500 in purchases. That's 5 percent cash back at different places each quarter, like grocery stores, on gas, and at restaurants. It pays to discover. Terms apply. See discover.com/five for details.

SPEAKER_2 (0:26)

This episode is brought to you by Schwab Market Update, an original podcast from Charles Schwab. Schwab Market Update, an original podcast from Charles Schwab, provides an information-packed daily market preview on stock updates, US and global economic news, monetary policy decisions, and key results and statistics that may impact your trading. Download the latest episode and subscribe at schwab.com/marketupdatepodcast, or find Schwab Market Update wherever you get your podcasts.

Jim Cramer (0:58)

Jim Cramer here to share a short preview of my take on the market from today's members-only CNBC Investing Club morning meeting. Join the club for full access to the morning meeting every day at 10:20 a.m. Visit cnbc.com/morningtake to sign up today. That's one word, morning take.

I have to tell you, I was quite struck by Larry Fink today. I'm obviously smarting that we're in Bank of New York, which collapsed for no particular reason. The report tomorrow, I don't want to touch it until then.

But Larry Fink was talking and was creating a bullish theory about the need for capital and how he's going to be able to provide new capital for compute. That is the NVIDIA case. He's getting the case of NVIDIA, what's going to happen. And I don't even want to say go buy NVIDIA because we're in a market that's fraught. And good news for individual stock is not necessarily going to translate right now into a stock that goes higher.

SPEAKER_4 (1:58)

Yeah, like even Goldman Sachs reported great numbers yesterday. What a quarter. I think it ended to the day slightly negative.

Even it was probably the best IB of the bunch this quarter between Morgan Stanley.

SPEAKER_2 (2:14)

Oh, it was the best.

SPEAKER_4 (2:15)

Yeah.

Jim Cramer (2:15)

I spoke to David last yesterday.

SPEAKER_6 (2:17)

And it's been hit hard, you know.

Jim Cramer (2:18)

And I would, and that's one of the stocks I want to highlight tomorrow because I get to speak, I'm lucky enough to be able to get to speak to a lot of these executives and of the ones that I thought had the best story, the best vision, it was Goldman Sachs. By the way, by far.

No, I mean, Jamie Dunn was not close to him at JP Morgan, so I do think that that is the one you want to buy.

SPEAKER_4 (2:42)

Wells fell 3% today, down again today. I think it's just dragged by Bank of America, which was the worst of the group.

Jim Cramer (2:50)

Right, Bank of America was always supposed to be the most, let's say boring and boring being good, but not this time. Don't worry about the OCC thing.

That was just something that the billion dollar fine. Look, they admitted to doing something, they didn't want to fight the regulators. It's not where you want to be. I do think that today is an outlying day, because when I see a Procter & Gamble highlight, a positive catalyst, and I see Cardinal Health, this once again, just screaming higher, I say to myself, okay, take a deep breath. Do you want to own Cardinal Health, and if you were a trader, you'd sell the Cardinal?

SPEAKER_4 (3:30)

Yeah, Cardinal Health really taking off the group has, since they renewed that contract with CVS, which we highlighted.

Jim Cramer (3:38)

This is the best one. Remember, we bought this, we got victimized by this, but here we go. The only one that's really come back from when we sold it was Danahurt's coming back.

And Danahurt's because that whole cohort's coming back, because people feel that there's going to be more investment by biotechs, because there's so many biotechs coming public.

SPEAKER_5 (4:00)

All opinions expressed by Jim Cramer on this podcast and in connection with the CNBC Investing Club are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Cramer. The opinions offered in connection with this podcast and the CNBC Investing Club are not an attempt to induce any particular trading behavior, investment or strategy. To view the full CNBC Investing Club disclaimer, please visit cnbc.com/investingclubdisclaimer.

SPEAKER_6 (4:32)

2 more minutes of transcript below

Thousands of transcripts fetched by people building searchable podcast archives

Fetch the whole transcript

The demo key returns a sample episode in full, no card needed:

request
curl -H "x-api-key: pt_demo" \
  https://spoken.md/transcripts/1000651996090

Markdown with the speakers named, for your notes, your knowledge base, or anything that makes HTTP calls.

From $0.10 per transcript. No subscription. Credits never expire. Prices exclude VAT, added at checkout for EU customers. Not what you expected? Email us within 14 days with 20 or fewer credits used and we refund the pack in full.

Using your own key:

request
curl -H "x-api-key: YOUR_KEY" \
  https://spoken.md/transcripts/1000796345335